Switzerland· 62627001
Ryzodeg Penfill, Injektionslösung
A insulin degludec und insulin aspart product containing insulinum degludecum, insulinum aspartum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Insulin degludec und insulin aspart is registered in 9 of 19 countries.
Countries holding a registration under ATC A10AD06 (insulin degludec und insulin aspart), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 6 of them publish a price we can compare per daily dose
Insulin degludec und insulin aspart · ATC A10AD06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- insulinum degludecum, insulinum aspartum
- Manufacturer
- Novo Nordisk Pharma AG
- Country
- Switzerland (CH)
- ATC code
- A10AD06
- ATC class
- Insulin degludec und Insulin aspart
- Defined daily dose
- 40 E, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806262700135x3 mlCHF 89.9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec und insulin aspart in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYZODEGNovo Nordisk A/S, Bagsvaerd
- SwedenRyzodeg FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- FinlandRyzodeg FlexPenNovo Nordisk A/S
- IcelandRyzodegNovo Nordisk A/S*
- NetherlandsRyzodeg 100 eenheden/ml oplossing voor injectie in patroonNovo Nordisk A.S.
- IrelandRyzodeg 100 units/mL solution for injectionNovo Nordisk A/S
- PolandRyzodegNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Ryzodeg Flexpen, Ryzodeg Flextouch
- Norway · Ryzodeg Flexpen, Ryzodeg Flextouch
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b85b6e7d-b34b-40ba-a781-1d720b391ac2 GET /v1/drugs/b85b6e7d-b34b-40ba-a781-1d720b391ac2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "insulinum degludecum 70 U + insulinum aspartum 30 U + insulinum analogum 100 U",
"valid_from": "2013-11-01",
"limitations": null,
"galenic_form": "Inj Lös",
"therapeutic_area": null,
"sl_inclusion_date": "2013-11-01",
"self_retention_pct": 10
}See everything about insulin degludec und insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.